JP7066639B2 - 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 - Google Patents

患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 Download PDF

Info

Publication number
JP7066639B2
JP7066639B2 JP2018562324A JP2018562324A JP7066639B2 JP 7066639 B2 JP7066639 B2 JP 7066639B2 JP 2018562324 A JP2018562324 A JP 2018562324A JP 2018562324 A JP2018562324 A JP 2018562324A JP 7066639 B2 JP7066639 B2 JP 7066639B2
Authority
JP
Japan
Prior art keywords
cells
lymphoma
peripheral
baseline
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018562324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519770A5 (enExample
JP2019519770A (ja
Inventor
エンデル，ヤン
ヴィンダーリヒ，マルク
ボクスハマー，ライナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys GmbH
Original Assignee
Morphosys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys GmbH filed Critical Morphosys GmbH
Publication of JP2019519770A publication Critical patent/JP2019519770A/ja
Publication of JP2019519770A5 publication Critical patent/JP2019519770A5/ja
Priority to JP2022072884A priority Critical patent/JP7511806B2/ja
Application granted granted Critical
Publication of JP7066639B2 publication Critical patent/JP7066639B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018562324A 2016-05-30 2017-05-30 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 Active JP7066639B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022072884A JP7511806B2 (ja) 2016-05-30 2022-04-27 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16171885 2016-05-30
EP16171885.3 2016-05-30
PCT/EP2017/063045 WO2017207574A1 (en) 2016-05-30 2017-05-30 Methods for predicting therapeutic benefit of anti-cd19 therapy in patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022072884A Division JP7511806B2 (ja) 2016-05-30 2022-04-27 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法

Publications (3)

Publication Number Publication Date
JP2019519770A JP2019519770A (ja) 2019-07-11
JP2019519770A5 JP2019519770A5 (enExample) 2020-07-16
JP7066639B2 true JP7066639B2 (ja) 2022-05-13

Family

ID=56116221

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018562324A Active JP7066639B2 (ja) 2016-05-30 2017-05-30 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法
JP2022072884A Active JP7511806B2 (ja) 2016-05-30 2022-04-27 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022072884A Active JP7511806B2 (ja) 2016-05-30 2022-04-27 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法

Country Status (26)

Country Link
US (2) US20190195879A1 (enExample)
EP (2) EP3465214B1 (enExample)
JP (2) JP7066639B2 (enExample)
KR (1) KR102416144B1 (enExample)
CN (2) CN115932265B (enExample)
AU (1) AU2017272608B2 (enExample)
CY (1) CY1124768T1 (enExample)
DK (2) DK3465214T3 (enExample)
EA (1) EA201892542A1 (enExample)
ES (2) ES2981046T3 (enExample)
FI (1) FI3916392T3 (enExample)
HR (2) HRP20210938T1 (enExample)
HU (2) HUE054860T2 (enExample)
IL (1) IL263103B2 (enExample)
LT (2) LT3465214T (enExample)
MA (2) MA45124B1 (enExample)
MD (2) MD3465214T2 (enExample)
MX (2) MX388502B (enExample)
PL (2) PL3465214T3 (enExample)
PT (2) PT3465214T (enExample)
RS (2) RS62155B1 (enExample)
SG (2) SG10201911958SA (enExample)
SI (2) SI3916392T1 (enExample)
SM (2) SMT202100291T1 (enExample)
WO (1) WO2017207574A1 (enExample)
ZA (2) ZA201808647B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CN114072424A (zh) 2019-05-03 2022-02-18 莫佛塞斯公司 具有有限数量的nk细胞的患者中的抗cd19疗法
WO2021084062A1 (en) * 2019-10-31 2021-05-06 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
TW202131950A (zh) * 2019-10-31 2021-09-01 德商莫菲西斯公司 依序抗ｃｄ１９療法
EP4168449A1 (en) * 2020-06-22 2023-04-26 MorphoSys AG Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
AU2021391623A1 (en) * 2020-12-04 2023-06-29 Incyte Corporation Anti-cd19 combination therapy
WO2026024668A1 (en) * 2024-07-22 2026-01-29 Abbott Laboratories Method of determining a volume of a liquid in a sample

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522511A (ja) 1998-08-11 2002-07-23 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法
US20100167315A1 (en) 2006-09-13 2010-07-01 Glycode Method for investigating the response to a treatment with a monoclonal antibody
JP2013543869A (ja) 2010-11-15 2013-12-09 メディミューン，エルエルシー Ｂ細胞リンパ腫のための併用療法
JP2014525926A (ja) 2011-08-16 2014-10-02 モルフォシス・アー・ゲー 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法
WO2016005548A1 (en) 2014-07-11 2016-01-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing hematological cancers

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
JP4361273B2 (ja) 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
PT1853718E (pt) * 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
CA2841738C (en) * 2011-08-16 2022-12-06 Morphosys Ag Combination therapy with an anti-cd19 antibody and a purine analog
EP2791165A4 (en) * 2011-12-12 2015-08-05 Pikamab Inc PREDICTING SENSITIVITY TO ANTIBODY MAINTENANCE THERAPY
US20130273032A1 (en) 2012-03-02 2013-10-17 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
CA2935748A1 (en) * 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
EP3157553A4 (en) * 2014-06-16 2018-02-28 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
JP6916741B2 (ja) 2015-05-26 2021-08-11 モルフォシス・アーゲー 抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HUE063119T2 (hu) 2017-05-31 2024-01-28 Morphosys Ag Kezelési paradigma anti-CD19 antitest és venetoclax kombinációs kezeléshez
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CN114072424A (zh) 2019-05-03 2022-02-18 莫佛塞斯公司 具有有限数量的nk细胞的患者中的抗cd19疗法
LT4051710T (lt) 2019-10-31 2026-03-10 Incyte Corporation Priešnavikinė kompleksinė terapija, apimanti anti-cd19 antikūną ir gama delta ląsteles
TW202131950A (zh) 2019-10-31 2021-09-01 德商莫菲西斯公司 依序抗ｃｄ１９療法
WO2021084062A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
EP4168449A1 (en) 2020-06-22 2023-04-26 MorphoSys AG Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
AU2021391623A1 (en) 2020-12-04 2023-06-29 Incyte Corporation Anti-cd19 combination therapy
US20230357392A1 (en) 2021-12-22 2023-11-09 Morphosys Ag Treatment Paradigm for an Anti-CD19 Antibody Therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522511A (ja) 1998-08-11 2002-07-23 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法
US20100167315A1 (en) 2006-09-13 2010-07-01 Glycode Method for investigating the response to a treatment with a monoclonal antibody
JP2013543869A (ja) 2010-11-15 2013-12-09 メディミューン，エルエルシー Ｂ細胞リンパ腫のための併用療法
JP2014525926A (ja) 2011-08-16 2014-10-02 モルフォシス・アー・ゲー 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法
WO2016005548A1 (en) 2014-07-11 2016-01-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing hematological cancers

Also Published As

Publication number Publication date
LT3465214T (lt) 2021-10-11
EP3916392A1 (en) 2021-12-01
US20220283166A1 (en) 2022-09-08
WO2017207574A1 (en) 2017-12-07
CY1124768T1 (el) 2022-11-25
CN109313194A (zh) 2019-02-05
DK3465214T3 (da) 2021-05-31
EA201892542A1 (ru) 2019-06-28
ES2878156T3 (es) 2021-11-18
CA3025823A1 (en) 2017-12-07
ES2981046T3 (es) 2024-10-07
KR20190013980A (ko) 2019-02-11
SI3465214T1 (sl) 2021-12-31
MX388502B (es) 2025-03-20
HUE067450T2 (hu) 2024-10-28
MA45124B1 (fr) 2021-05-31
DK3916392T3 (da) 2024-05-21
MA57021B1 (fr) 2024-05-31
KR102416144B1 (ko) 2022-07-04
FI3916392T3 (fi) 2024-06-03
JP7511806B2 (ja) 2024-07-08
LT3916392T (lt) 2024-08-26
RS62155B1 (sr) 2021-08-31
AU2017272608A1 (en) 2018-12-06
EP3916392B1 (en) 2024-05-01
MD3916392T2 (ro) 2024-10-31
CN115932265B (zh) 2026-04-14
MA45124A (fr) 2017-12-07
IL263103B1 (en) 2023-06-01
BR112018074603A2 (pt) 2019-03-19
ZA202100296B (en) 2025-05-28
PT3465214T (pt) 2021-06-30
EP3465214A1 (en) 2019-04-10
HRP20210938T1 (hr) 2021-09-03
US12631639B2 (en) 2026-05-19
SMT202100291T1 (it) 2021-07-12
IL263103B2 (en) 2023-10-01
ZA201808647B (en) 2021-05-26
JP2022119764A (ja) 2022-08-17
PT3916392T (pt) 2024-06-04
SG11201810159TA (en) 2018-12-28
HRP20240670T1 (hr) 2024-09-27
AU2017272608B2 (en) 2023-08-10
CN109313194B (zh) 2022-11-04
PL3916392T3 (pl) 2024-09-23
HUE054860T2 (hu) 2021-10-28
EP3465214B1 (en) 2021-04-28
MD3465214T2 (ro) 2021-09-30
SG10201911958SA (en) 2020-02-27
MX2018014702A (es) 2019-10-02
US20190195879A1 (en) 2019-06-27
NZ748468A (en) 2025-05-30
SMT202400204T1 (it) 2024-09-16
RS65540B1 (sr) 2024-06-28
MX2021014963A (es) 2022-02-24
PL3465214T3 (pl) 2021-12-20
JP2019519770A (ja) 2019-07-11
IL263103A (en) 2018-12-31
SI3916392T1 (sl) 2024-10-30
CN115932265A (zh) 2023-04-07

Similar Documents

Publication Publication Date Title
JP7511806B2 (ja) 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法
JP2023112043A (ja) 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
JP2026004466A (ja) 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
US20240310266A1 (en) Biomarkers for cancer and methods of use thereof
HK40065007A (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40065007B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40002753A (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40002753B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
EA040320B1 (ru) Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19
WO2026096859A2 (en) Biomarkers related to immunotherapy efficacy
BR112018074603B1 (pt) Método para identificar um sujeito tendo leucemia linfocítica crónica, e anticorpo anti-cd19
NZ788788A (en) Methods for predicting therapeutic benefit of anti-CD19 therapy in patients

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200601

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220314

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220427

R150 Certificate of patent or registration of utility model

Ref document number: 7066639

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250